Search
Atrasentan
go.drugbank.com/drugs/DB06199ApprovedInvestigational[L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist
Auranofin
go.drugbank.com/drugs/DB00995ApprovedInvestigationalHeme oxygenase 1 is an inducible heme-degrading enzyme with anti-inflammatory properties.
Synonyms: (1-Thio-beta-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate, 2,3,4,6-Tetra-O-acetyl-1-thio-beta-D-glucopyranosato-S (triethylphosphine)goldLoncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigationalZylonta also received approval in the EU on December 22, 2022.
Trioxsalen
go.drugbank.com/drugs/DB04571ApprovedWithdrawnIn research it can be conjugated to dyes for confocal microscopy and used to visualize sites of DNA damage.[3] The compound is has been explored for development of antisense oligonucleotides that can be
Calcitonin porcine
go.drugbank.com/drugs/DB13189ExperimentalThe first commercially available preparation in Britain was porcine calcitonin (brand name Calcitare).
Firocoxib
go.drugbank.com/drugs/DB09217ExperimentalVet approvedIt currently approved for veterinary use in dogs and horses under the brand names Equioxx and Previcox. Firocoxib was the first COX-2 inhibitor approved by the U.S.
Encorafenib
go.drugbank.com/drugs/DB11718ApprovedInvestigationalFDA-approved test. … approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an
Simeprevir
go.drugbank.com/drugs/DB06290ApprovedWithdrawnSimeprevir was approved by the FDA in November 2014 and is marketed under the brand name Olysio as oral tablets. … Sustained virologic response 12 weeks after planned end of treatment (SVR12) was achieved in 170/176 (97%) subjects without cirrhosis treated with 12 weeks simeprevir in combination with sofosbuvir (FDA
Dimethylthiambutene
go.drugbank.com/drugs/DB01444ExperimentalIllicitDimethylthiambutene (N,N-Dimethyl-1-methyl-3,3-di-2-thienylallylamine, Dimethibutin, Ohton) is an opioid analgesic drug. … It is now under international control under Schedule I of the UN Single Convention On Narcotic Drugs 1961, presumably due to high abuse potential, although little more information is available.
Synonyms: 3-dimethylamino-1,1-di-(2'-thienyl)-1-butene, N,N,1-trimethyl-3,3-di-2-thienylallylamineFluciclovine (18F)
go.drugbank.com/drugs/DB13146ApprovedInvestigational[A31385] Fluciclovine was developed by Blue Earth Diagnostics, Ltd. and FDA approved in May 27, 2016.[L1049]